[go: up one dir, main page]

MX2010003318A - Factor involucrado en la infeccion latente con herpesvirus y su uso. - Google Patents

Factor involucrado en la infeccion latente con herpesvirus y su uso.

Info

Publication number
MX2010003318A
MX2010003318A MX2010003318A MX2010003318A MX2010003318A MX 2010003318 A MX2010003318 A MX 2010003318A MX 2010003318 A MX2010003318 A MX 2010003318A MX 2010003318 A MX2010003318 A MX 2010003318A MX 2010003318 A MX2010003318 A MX 2010003318A
Authority
MX
Mexico
Prior art keywords
herpesvirus
latent infection
disorder
factor involved
mental
Prior art date
Application number
MX2010003318A
Other languages
English (en)
Inventor
Kazuhiro Kondo
Nobuyuki Kobayashi
Original Assignee
Virus Ikagaku Kenkyusho Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virus Ikagaku Kenkyusho Inc filed Critical Virus Ikagaku Kenkyusho Inc
Publication of MX2010003318A publication Critical patent/MX2010003318A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
    • C12N2710/16522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
    • C12N2710/16571—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/035—Herpes simplex virus I or II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se divulgan una prote?na y un gen, cada uno de los cuales es un factor que participa en la infecci?n latente con un herpesvirus. Se detect? un anticuerpo contra el factor en aproximadamente el 50% de los pacientes que sufren de trastornos mentales, considerando que el anticuerpo apenas se detect? en las personas sanas. Adem?s, un rat?n con SITH-1, introducido en ?l, desarroll? un trastorno mental tal como una enfermedad maniaco-depresiva o trastorno de la depresi?n. Bas?ndose en estos resultados, es posible proporcionar un m?todo para determinar objetivamente un trastorno mental y un modelo animal de un trastorno mental.
MX2010003318A 2007-09-27 2008-09-25 Factor involucrado en la infeccion latente con herpesvirus y su uso. MX2010003318A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007250461 2007-09-27
PCT/JP2008/067300 WO2009041501A1 (ja) 2007-09-27 2008-09-25 ヘルペスウイルスの潜伏感染に関与する因子及びその利用

Publications (1)

Publication Number Publication Date
MX2010003318A true MX2010003318A (es) 2010-04-09

Family

ID=40511384

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003318A MX2010003318A (es) 2007-09-27 2008-09-25 Factor involucrado en la infeccion latente con herpesvirus y su uso.

Country Status (15)

Country Link
US (5) US8431352B2 (es)
EP (2) EP2199391B1 (es)
JP (4) JP4920084B2 (es)
KR (1) KR101655486B1 (es)
CN (1) CN101809153B (es)
AU (1) AU2008304896B9 (es)
CA (1) CA2701668C (es)
EA (1) EA023557B1 (es)
ES (1) ES2554340T3 (es)
IL (2) IL204641A (es)
MX (1) MX2010003318A (es)
NZ (2) NZ584642A (es)
UA (1) UA101814C2 (es)
WO (1) WO2009041501A1 (es)
ZA (1) ZA201002424B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ584642A (en) 2007-09-27 2012-08-31 Japan Tobacco Inc Factor involved in latent infection with herpesvirus, and use thereof
US9657324B1 (en) 2008-10-03 2017-05-23 Virus Ikagaku Kenkyusho Inc. Method for treating or preventing mood disorders
BRPI1015445A2 (pt) * 2009-03-31 2016-04-19 Japan Tobacco Inc método para detecção de uma substância em amostra biológica
SG174938A1 (en) 2009-03-31 2011-11-28 Japan Tobacco Inc Method for detecting antibody against sith-1 in biological sample
CN105705657B (zh) * 2013-10-18 2020-07-28 Seegene株式会社 基于利用杂交-捕捉和模板化寡核苷酸的探测和标记寡核苷酸切割及延伸分析的在固相中的靶核酸序列检测
EP3163301B1 (en) * 2014-06-27 2019-08-07 Japan Tobacco, Inc. Method for treating, or preventing mood disorder
WO2016031581A1 (ja) * 2014-08-27 2016-03-03 株式会社ウイルス医科学研究所 疲労に関与する因子及びその利用
US10539578B2 (en) 2015-12-28 2020-01-21 Japan Tobacco Inc. Method for diagnosing, treating, or preventing mood disorders
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
CN109376816B (zh) * 2018-09-11 2022-04-01 广州金域医学检验中心有限公司 一种病理切片质量监控方法及其装置
WO2020202923A1 (ja) 2019-03-29 2020-10-08 日本たばこ産業株式会社 うつ病の評価方法及びうつ病の治療法の効果の評価方法、並びにうつ病若しくはうつ病の治療法の効果を評価するためのデータ取得方法
JP2024065869A (ja) 2022-10-31 2024-05-15 株式会社荏原製作所 基板処理装置、基板処理方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US823975A (en) 1905-08-07 1906-06-19 Harry B Smith Device for filling fountain-pens.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
LU86128A1 (fr) 1985-10-18 1987-06-02 Vander Poorten Henri Procede permettant l'impression ou le revetement de ceramique simultanement a son electroformage et conduisant en monocuisson a des produits decoratifs ou techniques
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
DE3901857A1 (de) 1989-01-23 1990-07-26 Boehringer Mannheim Gmbh Verfahren zur bestimmung von hiv 2 antikoerpern
ATE309376T1 (de) 1990-06-28 2005-11-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
GB9303157D0 (en) 1993-02-17 1993-03-31 Scotia Holdings Plc Treatment of a group of related disorders
JP3206311B2 (ja) 1994-07-29 2001-09-10 富士レビオ株式会社 抗体検出用試薬の非特異反応吸収剤
JP3517031B2 (ja) 1995-06-09 2004-04-05 日清紡績株式会社 生物学的活性物質の分析法
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
JPH11196870A (ja) 1998-01-08 1999-07-27 Katsuhiko Mikoshiba 受容体の機能解析法及びリガンド分子のスクリーニング法
JP2005532276A (ja) 2002-03-05 2005-10-27 ラモト アト テル−アヴィヴ ユニバーシティ リミテッド 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ開裂部位に対する免疫応答を誘発する方法
PL377091A1 (pl) 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
JP2004301646A (ja) 2003-03-31 2004-10-28 Sysmex Corp 免疫検査用非特異反応吸収剤
EP1681346A4 (en) 2003-08-29 2006-11-02 Soiken Inc HHV-6 OR HHV-7 DERIVED RECOMBINANT VIRUS VECTOR, METHOD FOR THE PRODUCTION THEREOF, METHOD FOR TRANSFORMING A HOST CELL USING THEREOF, TRANSFORMED HOST CELL AND GENE THERAPY METHOD USING THEREOF
WO2006006634A1 (ja) 2004-07-14 2006-01-19 Virus Ikagaku Kenkyusho Inc. 疲労度評価方法およびその利用
US20090068253A1 (en) 2005-09-06 2009-03-12 Guilford F Timothy Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione
AU2007317996B9 (en) 2006-11-01 2012-10-18 Beckman Coulter, Inc. Binding surfaces for affinity assays
EP1978365B1 (en) 2007-03-16 2010-08-25 Sysmex Corporation Reagent kit and method for measuring HCV antibody
JP4975601B2 (ja) 2007-03-16 2012-07-11 シスメックス株式会社 Ｈｃｖ抗体測定用試薬キット及びｈｃｖ抗体測定方法
US7972804B2 (en) 2007-07-03 2011-07-05 One Lambda Methods of detecting antibodies specific for denatured HLA antigens
BRPI0816103A2 (pt) 2007-08-28 2020-08-18 Japan Tobacco Inc. método para ligar proteínas a carregadores por fazer uso de tamavidinas.
NZ584642A (en) 2007-09-27 2012-08-31 Japan Tobacco Inc Factor involved in latent infection with herpesvirus, and use thereof
EP2267151A4 (en) 2008-03-31 2011-06-29 Japan Tobacco Inc METHOD FOR TITRATION OF VIRUSES
WO2009155379A2 (en) 2008-06-17 2009-12-23 Hhv-6 Foundation Artemisinin and derivatives thereof as antivirals
AU2010219698A1 (en) 2009-03-02 2011-10-13 Japan Tobacco Inc. Method for detecting substance in biological sample
SG174938A1 (en) 2009-03-31 2011-11-28 Japan Tobacco Inc Method for detecting antibody against sith-1 in biological sample
BRPI1015445A2 (pt) 2009-03-31 2016-04-19 Japan Tobacco Inc método para detecção de uma substância em amostra biológica
JP2013150553A (ja) 2012-01-24 2013-08-08 Osaka Bioscience Institute ＣａｒｔｐｔｍＲＮＡ発現細胞標識動物およびそれを用いたスクリーニング方法
JP2014019658A (ja) 2012-07-13 2014-02-03 Hiroshima Univ 抗−ｓ９７７リン酸化ｐｅｒ２特異的抗体
EP3163301B1 (en) 2014-06-27 2019-08-07 Japan Tobacco, Inc. Method for treating, or preventing mood disorder

Also Published As

Publication number Publication date
US10526374B2 (en) 2020-01-07
EA023557B1 (ru) 2016-06-30
US20100281550A1 (en) 2010-11-04
JP2013188210A (ja) 2013-09-26
CN101809153B (zh) 2014-01-01
IL204641A (en) 2013-08-29
AU2008304896A1 (en) 2009-04-02
NZ599590A (en) 2013-12-20
US20130217044A1 (en) 2013-08-22
JP2016006435A (ja) 2016-01-14
US20130137088A1 (en) 2013-05-30
ZA201002424B (en) 2011-02-23
WO2009041501A1 (ja) 2009-04-02
EP2987859A1 (en) 2016-02-24
UA101814C2 (ru) 2013-05-13
JP2012110329A (ja) 2012-06-14
EP2199391A1 (en) 2010-06-23
CA2701668A1 (en) 2009-04-02
IL219541A0 (en) 2012-06-28
AU2008304896B2 (en) 2014-07-31
US20170190745A1 (en) 2017-07-06
IL204641A0 (en) 2010-11-30
JP5829228B2 (ja) 2015-12-09
ES2554340T3 (es) 2015-12-18
EA201070400A1 (ru) 2010-10-29
JP5337232B2 (ja) 2013-11-06
JPWO2009041501A1 (ja) 2011-01-27
AU2008304896B9 (en) 2014-12-18
CA2701668C (en) 2017-07-11
NZ584642A (en) 2012-08-31
EP2199391A4 (en) 2011-01-19
AU2008304896A2 (en) 2010-05-27
EP2987859B1 (en) 2018-08-08
CN101809153A (zh) 2010-08-18
JP4920084B2 (ja) 2012-04-18
US10487118B2 (en) 2019-11-26
KR101655486B1 (ko) 2016-09-07
US8431352B2 (en) 2013-04-30
EP2199391B1 (en) 2015-11-11
KR20100074191A (ko) 2010-07-01
US20200071363A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
NZ584642A (en) Factor involved in latent infection with herpesvirus, and use thereof
Chinese Rheumatology Association 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis
WO2009117122A3 (en) Genetic analysis
WO2008137838A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2008070137A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2009063325A3 (en) Methods and systems for treating illnesses
MX2012010418A (es) Inhibidores syk de imidazopiridinas.
CY1114443T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
DK2413142T3 (da) Fremgangsmåde til forudsigelse af NSCLC-patienters reaktion på behandling med en EGFR-TK-inhibitor
EP2152346A4 (en) CONVECTION-STRENGTH DISTRIBUTION CATHETER WITH REMOVABLE STARTER AND APPLICATION METHOD THEREFOR
WO2007120480A3 (en) Systems and methods for predicting effectiveness in the treatment of psychiatric disorders, including depression
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
WO2007123976A3 (en) Antibody profiling for determination of patient responsiveness
WO2006002262A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
EP4296285A3 (en) Methods and systems for selection and treatment of patients with inflammatory diseases
WO2013083098A3 (en) Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors
WO2010124101A3 (en) Genetic markers associated with endometriosis and use thereof
MX2014000204A (es) Metodo de administracion y tratamiento.
WO2009027703A3 (en) Identifying organ damage
WO2010102160A3 (en) Diagnostic method using palb2
Randolph Fatigue risk management
WO2008008487A3 (en) Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
MA34381B1 (fr) Procédé de prédiction de réponse thérapeutique chez des patients atteints de sclérose en plaques
WO2007084734A3 (en) Method to determine and biomarker for treatment efficacy with ssri, snri, and sari antidepressants

Legal Events

Date Code Title Description
FG Grant or registration